Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Nabil Abadir_2023
VIEWPOINTS

Nabil Abadir, CMO and Head of Global Medical Affairs at Amarin Corp Shares Insights from New Data Evaluating Vascepa/Vazkepa at ACC.23/WCC

Shots: Nabil spoke about the data evaluating Vascepa/Vazkepa and eicosapentaenoic acid in reducing cardiovascular events presented at the ACC.23/WCC He also told our readers about the new analysis from the REDUCE-IT trial showing the effectiveness of VASCEPA/VAZKEPA in patients with recent acute coronary syndrome The interview shows how Amarin is developing innovative therapies, increasing the…
July 18, 2023

Read more

VIEWPOINTS_Avery Ince_2023
VIEWPOINTS

Avery Ince, VP, Medical Affairs – CVM Franchise, Janssen Shares his Views on New Data from P-III VOYAGER PAD Trial

Shots: Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023 The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…
June 5, 2023

Read more

VIEWPOINTS_Jason-Winnike_2023
VIEWPOINTS

Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel

Shots: Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features  He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer  The interview gives a profound understanding…
March 6, 2023

Read more

Viewpoints_Matt Killeen
VIEWPOINTS

Matt Killeen, CSO at Renovacor Shares Insights on Pipeline Expansion through its AAV Gene Therapy Program

Shots: Matt spoke about the new research program for multiple genetic segments of arrhythmogenic cardiomyopathy He also highlighted Renovacor’s research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) The interview shows Renovacor’s pipeline expansion to develop transformative therapies in genetically-driven cardiovascular diseases Smriti: Please give readers a brief insight…
September 12, 2022

Read more

PharmaShots Interview Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results
VIEWPOINTS

PharmaShots Interview: Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results

Shots: Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022 He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseases The interview summarizes…
August 3, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]